Literature DB >> 10315481

Benefits of a community-hospital pulmonary rehabilitation program.

R W Wright, D F Larsen, R G Monie, R A Aldred.   

Abstract

Pulmonary rehabilitation can be a beneficial and cost-effective mode of therapy for patients with chronic obstructive pulmonary disease (COPD). At St Joseph's Hospital in Stockton, California, we established a multi-disciplinary, 10-week program combining outpatient education with aerobic exercise to promote both improved subjective well-being and increased exercise tolerance in patients with COPD. We studied 74 patients who had completed the program at least 1 year before the study began. Subjective data about the program were collected by use of a questionnaire. Changes in physical work capacity were measured by use of stress tests performed before and after the program was completed. Of the 57 patients responding to the questionnaire, most felt that the program had improved the quality of their lives. After the program was completed, significant decreases were seen in oxygen consumption, minute ventilation, and heart rate during treadmill exercise. The number of days of hospitalization for the group decreased from 497 in the year before completing the program to 34 the year after.

Entities:  

Mesh:

Year:  1983        PMID: 10315481

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  3 in total

Review 1.  An economic overview of chronic obstructive pulmonary disease.

Authors:  H S Ruchlin; E J Dasbach
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 2.  Exercise and training in patients with chronic obstructive lung disease.

Authors:  N J Cox; C L van Herwaarden; H Folgering; R A Binkhorst
Journal:  Sports Med       Date:  1988-09       Impact factor: 11.136

Review 3.  Effects of physical activity in mild to moderate COPD: a systematic review.

Authors:  Niels Chavannes; J J H Vollenberg; C P van Schayck; E F M Wouters
Journal:  Br J Gen Pract       Date:  2002-07       Impact factor: 5.386

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.